{"id":"NCT04576988","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","briefTitle":"A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-01-25","primaryCompletion":"2022-08-26","completion":"2022-12-06","firstPosted":"2020-10-06","resultsPosted":"2023-08-23","lastUpdate":"2024-09-19"},"enrollment":324,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"BIOLOGICAL","name":"Sotatercept","otherNames":["MK-7962","ACE-011"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Background PAH Therapy","otherNames":[]}],"arms":[{"label":"Sotatercept plus background PAH therapy","type":"EXPERIMENTAL"},{"label":"Placebo plus background PAH therapy","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are to evaluate the efficacy and safety of sotatercept (MK-7962) treatment (plus background pulmonary arterial hypertension (PAH) therapy) versus placebo (plus background PAH therapy) at 24 weeks in adults with PAH. The primary hypothesis of the study is that the participants receiving sotatercept will have improved 6-minute walk distance (6MWD) at 24 weeks compared to participants receiving placebo.","primaryOutcome":{"measure":"Change From Baseline in 6-Minute Walk Distance (6MWD) at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Sotatercept Plus Background PAH Therapy (DBPC Period)","deltaMin":34.4,"sd":null},{"arm":"Placebo Plus Background PAH Therapy (DBPC Period)","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":25},"locations":{"siteCount":120,"countries":["United States","Argentina","Australia","Belgium","Brazil","Canada","Czechia","France","Germany","Israel","Italy","Mexico","Netherlands","New Zealand","Poland","Serbia","South Korea","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["36877098","40526255","37851297","37696565"],"seeAlso":["http://www.merckclinicaltrials.com","https://msd.trialsummaries.com/Study/StudyDetails?id=26050&tenant=MT_MSD_9011"]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":163},"commonTop":["COVID-19","Headache","Epistaxis","Nausea","Fatigue"]}}